ARS Pharmaceuticals Inc (NAS:SPRY)

$ 11.41 0.21 (1.88%) Market Cap: 1.11 Bil Enterprise Value: 904.36 Mil PE Ratio: 0 PB Ratio: 5.51 GF Score: 18/100

Q3 2024 ARS Pharmaceuticals Inc Earnings Call Transcript
Nov 13, 2024

$14.08 (-15.23%)

Earnings
ARS Pharmaceuticals Inc at SVB Securities Global Biopharma Conference (Virtual) Transcript
Feb 16, 2023
Silverback Therapeutics Inc and ARS Pharmaceuticals Inc Merger Announcement Call Transcript
Jul 21, 2022
Silverback Therapeutics Inc Strategic Prioritization and Corporate Update Call Transcript
Mar 31, 2022
Silverback Therapeutics Inc at SVB Leerink Global Healthcare (Virtual) Transcript
Feb 16, 2022
Silverback Therapeutics Inc at H C Wainwright Bioconnect Conference (Virtual) Transcript
Jan 10, 2022
Silverback Therapeutics Inc SBT6050 Clinical Data Update Call Transcript
Sep 16, 2021

Silverback Therapeutics Inc Strategic Prioritization and Corporate Update Call Transcript

Mar 31, 2022 / 09:00PM GMT

Transcript 10-K8-K

Operator

Welcome to the Silverback Therapeutics update on the strategic priorities. (Operator Instructions) I would now like to hand the conference over to Jonathan Piazza, Chief Financial Officer of Silverback Therapeutics. The floor is yours.

Jonathan Piazza

Silverback Therapeutics Inc. - CFO

Thank you, operator. Good afternoon, and welcome to the Silverback webcast to discuss an update on our strategic priorities. Following market close today, March 31, we filed our Form 10-K and issued a press release detailing our strategic reprioritization and our financial results for the fourth quarter and full year ended 2021.

Starting on slide 2, you will be making forward-looking statements in this presentation, including statements regarding our business and the expected timing and impact of future events. Filings made with the Securities and Exchange Commission, including 10-K and 10-Q reports describe various risks relating to these statements. You are cautioned not to place undue reliance on these forward-looking statements, and Silverback disclaims any

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.